Dehaier Medical Receives US$20 Million Strategic Investment from Liaison Interactive

BEIJING, April 28, 2016 -- Dehaier Medical Systems Ltd. (DHRM) ("Dehaier Medical" or the "Company"), which develops, markets and sells medical devices and wearable sleep respiratory products in China and international markets, today announced that it entered into a definitive securities purchase agreement (the "Agreement") with Hangzhou Liaison Interactive Information Technology Co. Ltd. ("Liaison Interactive" or the "Purchaser"), a publicly listed company on the Shenzhen Stock Exchange (Trading Ticker: 002280) pursuant to which the Liaison Interactive has agreed to purchase 11,111,111 restricted common shares of the Company (the "Shares") for an aggregate of US$20,000,000 (the "Purchase Price"). The Purchase Price is US$1.80 per share, which represents a 35% premium to Dehaier Medical's closing price of $1.33 on April 27, 2016.
In consideration of the payment by the Buyer of the Purchase Price, the Buyer and its designees will also receive warrants to purchase 1,000,000 restricted common shares of the Company at a purchase price of US$2.20 per share (the "Warrants").  The Warrants are exercisable by the Buyer or its designees in whole or in part and are exercisable at any time after the Closing.
Read more: Dehaier Medical Systems Ltd ( DHRM )

Auris Surgical Robotics Agrees to Acquire Hansen Medical


Auris Surgical Robotics, Inc. and Hansen Medical, Inc. (NASDAQ: HNSN) today announced that they have signed a definitive merger agreement under which Auris will acquire Hansen Medical for $4.00 per share in cash, or a total equity value of approximately $80 million. The purchase price per share represents a premium of approximately 39.9% over the closing sale price of common stock of Hansen Medical as reported on NASDAQ on April 19, 2016. In addition, certain significant stockholders of Hansen Medical have agreed to invest approximately $49 million into Auris contemporaneously with the closing of the transaction.

"Hansen Medical has developed a technology leadership position in the field of intravascular robotics," commented Dr. Fred Moll, Chief Executive Officer of Auris. "There remains a significant opportunity in flexible robotics and I am excited to combine with Hansen Medical to advance this market."

Read more: Hansen Medical Inc ( HNSN )

Great Basin Announces Q1 Revenues and Customer Acquisition Results

2016-04-14 16:01 ET - Company sees 59.4% growth in revenue, and 119.8% customer growth year-over-year; will provide customer acquisition targets and 2016-2017 product roadmap on Business Update Call later today

SALT LAKE CITY -- Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, today reported preliminary revenue results for the first quarter 2016. For the first quarter 2016, revenue was $731,422, an increase of 59.4% over the first quarter of 2015. The Company also reported that its customer base of revenue generating customers grew to 222 as of March 31, 2016, an increase of 119.8% over first quarter last year. The company will provide guidance for the 2016-2017 customer acquisition targets and menu expansion on a call later today.

Read more: Great Basin Scientific Inc ( GBSN )

Amedica Signs Exclusive Chinese Silicon Nitride Distribution Agreement

SALT LAKE CITY, UT -- 2016-04-18 Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce a partnership with Shandong Weigao Orthopedic Device Company Limited ("Weigao Orthopedic"), a subsidiary of Shandong Weigao Group Medical Polymer Company Limited (HKSE: 1066), a medical device company in China specializing in the R&D, production and sale of spine, trauma and joint orthopedic implants.

Under the distribution agreement, Weigao Orthopedic will have exclusive rights for the sale, marketing and distribution of Amedica-branded silicon nitride spinal implants in the People's Republic of China, and will abide by minimum annual purchase requirements in Year 1 of 20,000 units, growing annually to 50,000 units in Year 6, following regulatory clearance by the China Food and Drug Administration (CFDA). Weigao Orthopedic will leverage its expertise in acquiring CFDA clearance of medical devices, in order to accelerate Chinese clearance of Amedica's products.

Read more: Amedica Corporation ( AMDA )

Cardiovascular Systems Reports Stronger Than Expected Preliminary Fiscal Third-Quarter Revenue

Company Implements Restructuring to Align Costs with Expected Revenue Growth and Provide a Pathway to Profitability
ST. PAUL, Minn. -- Cardiovascular Systems, Inc. (CSI) (CSII) today reported preliminary revenue for its fiscal third quarter ended March 31, 2016. For the quarter, the company anticipates revenue to range from $43.5 million to $44 million, approximately 4 percent to 5 percent above the high end of its previously issued guidance range of $40.5 million to $42 million. Additionally, CSI announced broad-based restructuring measures to reduce costs as a key part of its plan to balance revenue growth with a pathway to profitability and positive cash flow. The restructuring measures include a workforce reduction of approximately 8 percent.
Read more: Cardiovascular Systems Inc ( CSI )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker